Nordea Investment Management AB boosted its stake in Johnson & Johnson (NYSE:JNJ) by 2.0% during the third quarter, Holdings Channel reports. The institutional investor owned 10,047,087 shares of the company’s stock after buying an additional 196,968 shares during the period. Johnson & Johnson accounts for approximately 3.1% of Nordea Investment Management AB’s investment portfolio, making the stock its 3rd largest position. Nordea Investment Management AB owned 0.37% of Johnson & Johnson worth $1,186,862,000 as of its most recent filing with the SEC.
Several other large investors have also recently modified their holdings of JNJ. Americafirst Capital Management LLC bought a new stake in shares of Johnson & Johnson during the second quarter worth $101,000. Tuttle Tactical Management LLC bought a new stake in shares of Johnson & Johnson during the second quarter worth $103,000. Lenox Wealth Management Inc. boosted its stake in shares of Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock worth $118,000 after buying an additional 190 shares during the period. Thomas J. Herzfeld Advisors Inc. boosted its stake in shares of Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock worth $122,000 after buying an additional 690 shares during the period. Finally, NCM Capital Management Group Inc. bought a new stake in shares of Johnson & Johnson during the second quarter worth $127,000. Institutional investors and hedge funds own 65.28% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) traded up 1.17% during trading on Friday, hitting $113.15. The stock had a trading volume of 3,914,395 shares. The stock’s 50 day moving average price is $114.87 and its 200 day moving average price is $117.84. Johnson & Johnson has a 12-month low of $99.78 and a 12-month high of $126.07. The firm has a market cap of $307.83 billion, a P/E ratio of 19.08 and a beta of 0.72.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, January 24th. The company reported $1.58 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.56 by $0.02. The firm earned $18.10 billion during the quarter, compared to the consensus estimate of $18.28 billion. Johnson & Johnson had a return on equity of 25.61% and a net margin of 22.78%. The firm’s revenue was up 1.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.44 EPS. On average, analysts anticipate that Johnson & Johnson will post $7.10 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 14th. Shareholders of record on Tuesday, February 28th will be paid a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a yield of 2.86%. The ex-dividend date is Friday, February 24th. Johnson & Johnson’s dividend payout ratio is presently 54.42%.
A number of research firms have commented on JNJ. Zacks Investment Research cut Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Tuesday, January 3rd. Goldman Sachs Group, Inc. (The) decreased their price target on Johnson & Johnson from $120.00 to $115.00 and set a “neutral” rating for the company in a research note on Wednesday. Wells Fargo & Company cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and increased their price target for the company from $112.28 to $112.80 in a research note on Thursday. Vetr cut Johnson & Johnson from a “buy” rating to a “hold” rating and set a $119.60 price target for the company. in a research note on Tuesday, November 1st. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $107.00 price target on shares of Johnson & Johnson in a research note on Tuesday, December 20th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eight have given a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus price target of $121.83.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).